# Mediar Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mediar-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.mediartx.com
- Total disclosed funding: $95M
- Latest round: Series B (Dec 10, 2025)
- Investors on record: 15

## About

Founded in 2018 and based in Massachusetts, US, Mediar Therapeutics, Inc. is a discovery-stage company developing new treatments for fibrosis. The company was founded by Mass General Brigham Ventures. The firm’s foundational technology is based on pioneering research from Massachusetts General Hospital and Brigham and Women's Hospital. In December 2025, Mediar Therapeutics, Inc. raised USD 37.85 million in series B funding from new investors Amplitude, Asahi Kasei Corporate Venture Capital, Intermediate Capital Group, and Longwood Fund, with participation from returning investors Ono Venture Investment, Pfizer Venture Investments, Eli Lilly & Company, Bristol-Myers Squibb Company, and Novartis Venture Fund.

The company’s platform and pipeline are based on an emerging class of novel targets, fibrotic mediators that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

The company plans to use the December 2025 funding to advance its research and development programs, expand scientific initiatives, and progress its therapeutic candidates toward preclinical and clinical stages.

## Funding rounds

- Series B, Dec 10, 2025, $38M — Intermediate Capital Group, Novartis Venture Fund, Longwood Fund, Pfizer Venture Investments, Eli Lilly & Company, Bristol-Myers Squibb Company, Amplitude, Asahi Kasei Corporate Venture Capital, Ono Venture Investment
- Series A, Nov 18, 2022, $32M — Sofinnova Partners, Novartis Venture Fund, Gimv, Bristol-Myers Squibb Company, Pfizer Venture Investments, Mass General Brigham Ventures, Eli Lilly & Company, Mission Biocapital, Pureos Bioventures, Ono Venture Investment
- Seed, Mar 17, 2021, $20M — Pfizer Venture Investments, Mission Biocapital, Agent Capital, Ono Venture Investment
- Seed, Jun 1, 2019 — Mass General Brigham Ventures
- Seed, Jan 29, 2019, $5M — Agent Capital

## Investors

- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Seed
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Seed, Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Seed, Series A, Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed, Series A
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Seed, Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A
- Bristol-Myers Squibb Company — Series A, Series B
- Eli Lilly & Company — Series A, Series B
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A
- Intermediate Capital Group — Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series B
- Asahi Kasei Corporate Venture Capital — Series B